Dataset Information


A case of Alemtuzumab-induced neutropenia in multiple sclerosis in association with the expansion of large granular lymphocytes.



Alemtuzumab has been demonstrated to reduce the risks of relapse and accumulation of sustained disability in Multiple Sclerosis (MS) patients compared to ?-interferon. It acts against CD52, leading primarily to lymphopenia. Recent data have shown that mild neutropenia is observed in 16% of treated MS-patients whereas severe neutropenia occurred in 0.6%.

Case presentation

Herein, we present the case of a 34-year-old woman with relapsing-remitting MS, with a history of treatment with glatiramer acetate and natalizumab, who subsequently received Alemtuzumab (12 mg / 24 h?×?5 days). 70-days after the last Alemtuzumab administration, the patient displayed neutropenia (500 neutrophils/?L) with virtual absence of B-cells (0.6% of total lymphocytes), low values of CD4-T-cells (6.6%) and predominance of CD8-T-cells (48%) and NK-cells (47%); while large granular lymphocytes (LGL) predominated in the blood-smear examination. Due to prolonged neutropenia (5-days) the patient was placed on low-dose corticosteroids leading to sustained remission.


This is the first case of a patient with relapsing-remitting MS with neutropenia two months post-Alemtuzumab, with simultaneous presence of LGL cells in the blood and a robust therapeutic response to prednisolone. We recommend testing with a complete blood count every 15 days in the first 3 months after the 1st Alemtuzumab administration and searching for large granular lymphocytes cell expansion on microscopic examination of the peripheral blood if neutropenia develops.


PROVIDER: S-EPMC6206708 | BioStudies | 2018-01-01

REPOSITORIES: biostudies

Similar Datasets

2020-01-01 | S-EPMC7750777 | BioStudies
2019-01-01 | S-EPMC7650051 | BioStudies
2015-01-01 | S-EPMC4361497 | BioStudies
2020-01-01 | S-EPMC6865853 | BioStudies
2019-01-01 | S-EPMC6439772 | BioStudies
2012-01-01 | S-EPMC3464048 | BioStudies
1000-01-01 | S-EPMC5063395 | BioStudies
2020-01-01 | S-EPMC7443992 | BioStudies
1000-01-01 | S-EPMC5626941 | BioStudies
2015-01-01 | S-EPMC4542714 | BioStudies